0

Close
 
Upcoming Allied Market Research
2023
Flunarizine Hydrochloride Market

Flunarizine Hydrochloride Market

by Drug Formulation (Tablets, Capsules) and by Application (Migraine, Vertigo): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals
Report Code: A03648
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Flunarizine Hydrochloride Market

Request Now !

Flunarizine hydrochloride is a calcium antagonist drug that acts by reducing or preventing migraine headaches. This drug is used to treat dizziness and vertigo.

Growth in the prevalence of migraine, increasing consumption of junk food, smoking & drinking, and hectic & stressful lifestyle that leads to migraines drive the flunarizine hydrochloride market growth. Furthermore, increasing awareness of healthcare among the population and low cost of flunarizine hydrochloride are anticipated to boost the market growth. However, adverse effects, presence of substitutes such as amlodipine, and stringent government regulations related to the safety & efficacy of flunarizine hydrochloride hinder the market growth.

In addition, flunarizine is not available on prescription in the U.S. and Japan, thereby hampering the market growth. Ongoing R&D activities related to flunarizine hydrochloride are anticipated to present new opportunities for the market.

The market is segmented on the basis of application, drug formulation, and region. Based on application, the market is categorized into migraine and vertigo. By drug formulation, it is bifurcated into tablets and capsules. The geographical breakdown of each of the aforesaid segments has been covered for North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits

  • The study provides an in-depth analysis of the global flunarizine hydrochloride market with current trends and future estimations to elucidate investment pockets.
  • Comprehensive analysis of factors that drive and restrict the growth of the market has been provided.
  • The report provides a quantitative analysis to help stakeholders to capitalize on prevailing market opportunities.
  • Extensive analysis of different segments helps understand various products of the market.
  • Key players have been profiled and their strategies thoroughly analyzed, which predict the competitive outlook of the market.

 Flunarizine Hydrochloride Market Report Highlights

Aspects Details
By Drug Formulation
  • Tablets
  • Capsules
By Application
  • Migraine
  • Vertigo
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players Fdc Ltd, Torrent Pharmaceuticals Ltd, Cadila Pharmaceuticals Ltd, Orchid Chemicals and Pharmaceuticals Ltd, Cipla Limited, Intas Pharmaceuticals Ltd, Johnson and Johnson, Karnataka Antibiotics and Pharmaceuticals Ltd, Alkem Laboratories Ltd, Aa Pharma Inc
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: FLUNARIZINE HYDROCHLORIDE MARKET, BY DRUG FORMULATION

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Drug Formulation

    • 4.2. Tablets

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Capsules

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

  • CHAPTER 5: FLUNARIZINE HYDROCHLORIDE MARKET, BY APPLICATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Application

    • 5.2. Migraine

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Vertigo

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

  • CHAPTER 6: FLUNARIZINE HYDROCHLORIDE MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Drug Formulation

      • 6.2.3. Market Size and Forecast, By Application

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Flunarizine Hydrochloride Market

        • 6.2.5.1. Market Size and Forecast, By Drug Formulation
        • 6.2.5.2. Market Size and Forecast, By Application

      • 6.2.6. Canada Flunarizine Hydrochloride Market

        • 6.2.6.1. Market Size and Forecast, By Drug Formulation
        • 6.2.6.2. Market Size and Forecast, By Application

      • 6.2.7. Mexico Flunarizine Hydrochloride Market

        • 6.2.7.1. Market Size and Forecast, By Drug Formulation
        • 6.2.7.2. Market Size and Forecast, By Application

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Drug Formulation

      • 6.3.3. Market Size and Forecast, By Application

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Flunarizine Hydrochloride Market

        • 6.3.5.1. Market Size and Forecast, By Drug Formulation
        • 6.3.5.2. Market Size and Forecast, By Application

      • 6.3.6. Germany Flunarizine Hydrochloride Market

        • 6.3.6.1. Market Size and Forecast, By Drug Formulation
        • 6.3.6.2. Market Size and Forecast, By Application

      • 6.3.7. Italy Flunarizine Hydrochloride Market

        • 6.3.7.1. Market Size and Forecast, By Drug Formulation
        • 6.3.7.2. Market Size and Forecast, By Application

      • 6.3.8. Spain Flunarizine Hydrochloride Market

        • 6.3.8.1. Market Size and Forecast, By Drug Formulation
        • 6.3.8.2. Market Size and Forecast, By Application

      • 6.3.9. UK Flunarizine Hydrochloride Market

        • 6.3.9.1. Market Size and Forecast, By Drug Formulation
        • 6.3.9.2. Market Size and Forecast, By Application

      • 6.3.10. Russia Flunarizine Hydrochloride Market

        • 6.3.10.1. Market Size and Forecast, By Drug Formulation
        • 6.3.10.2. Market Size and Forecast, By Application

      • 6.3.11. Rest Of Europe Flunarizine Hydrochloride Market

        • 6.3.11.1. Market Size and Forecast, By Drug Formulation
        • 6.3.11.2. Market Size and Forecast, By Application

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Drug Formulation

      • 6.4.3. Market Size and Forecast, By Application

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Flunarizine Hydrochloride Market

        • 6.4.5.1. Market Size and Forecast, By Drug Formulation
        • 6.4.5.2. Market Size and Forecast, By Application

      • 6.4.6. Japan Flunarizine Hydrochloride Market

        • 6.4.6.1. Market Size and Forecast, By Drug Formulation
        • 6.4.6.2. Market Size and Forecast, By Application

      • 6.4.7. India Flunarizine Hydrochloride Market

        • 6.4.7.1. Market Size and Forecast, By Drug Formulation
        • 6.4.7.2. Market Size and Forecast, By Application

      • 6.4.8. South Korea Flunarizine Hydrochloride Market

        • 6.4.8.1. Market Size and Forecast, By Drug Formulation
        • 6.4.8.2. Market Size and Forecast, By Application

      • 6.4.9. Australia Flunarizine Hydrochloride Market

        • 6.4.9.1. Market Size and Forecast, By Drug Formulation
        • 6.4.9.2. Market Size and Forecast, By Application

      • 6.4.10. Thailand Flunarizine Hydrochloride Market

        • 6.4.10.1. Market Size and Forecast, By Drug Formulation
        • 6.4.10.2. Market Size and Forecast, By Application

      • 6.4.11. Malaysia Flunarizine Hydrochloride Market

        • 6.4.11.1. Market Size and Forecast, By Drug Formulation
        • 6.4.11.2. Market Size and Forecast, By Application

      • 6.4.12. Indonesia Flunarizine Hydrochloride Market

        • 6.4.12.1. Market Size and Forecast, By Drug Formulation
        • 6.4.12.2. Market Size and Forecast, By Application

      • 6.4.13. Rest of Asia Pacific Flunarizine Hydrochloride Market

        • 6.4.13.1. Market Size and Forecast, By Drug Formulation
        • 6.4.13.2. Market Size and Forecast, By Application

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Drug Formulation

      • 6.5.3. Market Size and Forecast, By Application

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Flunarizine Hydrochloride Market

        • 6.5.5.1. Market Size and Forecast, By Drug Formulation
        • 6.5.5.2. Market Size and Forecast, By Application

      • 6.5.6. South Africa Flunarizine Hydrochloride Market

        • 6.5.6.1. Market Size and Forecast, By Drug Formulation
        • 6.5.6.2. Market Size and Forecast, By Application

      • 6.5.7. Saudi Arabia Flunarizine Hydrochloride Market

        • 6.5.7.1. Market Size and Forecast, By Drug Formulation
        • 6.5.7.2. Market Size and Forecast, By Application

      • 6.5.8. UAE Flunarizine Hydrochloride Market

        • 6.5.8.1. Market Size and Forecast, By Drug Formulation
        • 6.5.8.2. Market Size and Forecast, By Application

      • 6.5.9. Argentina Flunarizine Hydrochloride Market

        • 6.5.9.1. Market Size and Forecast, By Drug Formulation
        • 6.5.9.2. Market Size and Forecast, By Application

      • 6.5.10. Rest of LAMEA Flunarizine Hydrochloride Market

        • 6.5.10.1. Market Size and Forecast, By Drug Formulation
        • 6.5.10.2. Market Size and Forecast, By Application

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning,2022

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Johnson And Johnson

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Cipla Limited

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Torrent Pharmaceuticals Ltd

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Aa Pharma Inc

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Karnataka Antibiotics And Pharmaceuticals Ltd

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Cadila Pharmaceuticals Ltd

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Orchid Chemicals And Pharmaceuticals Ltd

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Fdc Ltd

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. Alkem Laboratories Ltd

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Intas Pharmaceuticals Ltd

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL FLUNARIZINE HYDROCHLORIDE MARKET, BY DRUG FORMULATION, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL FLUNARIZINE HYDROCHLORIDE MARKET FOR TABLETS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL FLUNARIZINE HYDROCHLORIDE MARKET FOR CAPSULES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL FLUNARIZINE HYDROCHLORIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL FLUNARIZINE HYDROCHLORIDE MARKET FOR MIGRAINE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL FLUNARIZINE HYDROCHLORIDE MARKET FOR VERTIGO, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL FLUNARIZINE HYDROCHLORIDE MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. NORTH AMERICA FLUNARIZINE HYDROCHLORIDE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. NORTH AMERICA FLUNARIZINE HYDROCHLORIDE, BY DRUG FORMULATION, 2022-2032 ($MILLION)
  • TABLE 10. NORTH AMERICA FLUNARIZINE HYDROCHLORIDE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 11. U.S. FLUNARIZINE HYDROCHLORIDE, BY DRUG FORMULATION, 2022-2032 ($MILLION)
  • TABLE 12. U.S. FLUNARIZINE HYDROCHLORIDE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 13. CANADA FLUNARIZINE HYDROCHLORIDE, BY DRUG FORMULATION, 2022-2032 ($MILLION)
  • TABLE 14. CANADA FLUNARIZINE HYDROCHLORIDE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 15. MEXICO FLUNARIZINE HYDROCHLORIDE, BY DRUG FORMULATION, 2022-2032 ($MILLION)
  • TABLE 16. MEXICO FLUNARIZINE HYDROCHLORIDE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 17. EUROPE FLUNARIZINE HYDROCHLORIDE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. EUROPE FLUNARIZINE HYDROCHLORIDE, BY DRUG FORMULATION, 2022-2032 ($MILLION)
  • TABLE 19. EUROPE FLUNARIZINE HYDROCHLORIDE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 20. FRANCE FLUNARIZINE HYDROCHLORIDE, BY DRUG FORMULATION, 2022-2032 ($MILLION)
  • TABLE 21. FRANCE FLUNARIZINE HYDROCHLORIDE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 22. GERMANY FLUNARIZINE HYDROCHLORIDE, BY DRUG FORMULATION, 2022-2032 ($MILLION)
  • TABLE 23. GERMANY FLUNARIZINE HYDROCHLORIDE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 24. ITALY FLUNARIZINE HYDROCHLORIDE, BY DRUG FORMULATION, 2022-2032 ($MILLION)
  • TABLE 25. ITALY FLUNARIZINE HYDROCHLORIDE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 26. SPAIN FLUNARIZINE HYDROCHLORIDE, BY DRUG FORMULATION, 2022-2032 ($MILLION)
  • TABLE 27. SPAIN FLUNARIZINE HYDROCHLORIDE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 28. UK FLUNARIZINE HYDROCHLORIDE, BY DRUG FORMULATION, 2022-2032 ($MILLION)
  • TABLE 29. UK FLUNARIZINE HYDROCHLORIDE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 30. RUSSIA FLUNARIZINE HYDROCHLORIDE, BY DRUG FORMULATION, 2022-2032 ($MILLION)
  • TABLE 31. RUSSIA FLUNARIZINE HYDROCHLORIDE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 32. REST OF EUROPE FLUNARIZINE HYDROCHLORIDE, BY DRUG FORMULATION, 2022-2032 ($MILLION)
  • TABLE 33. REST OF EUROPE FLUNARIZINE HYDROCHLORIDE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 34. ASIA-PACIFIC FLUNARIZINE HYDROCHLORIDE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 35. ASIA-PACIFIC FLUNARIZINE HYDROCHLORIDE, BY DRUG FORMULATION, 2022-2032 ($MILLION)
  • TABLE 36. ASIA-PACIFIC FLUNARIZINE HYDROCHLORIDE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 37. CHINA FLUNARIZINE HYDROCHLORIDE, BY DRUG FORMULATION, 2022-2032 ($MILLION)
  • TABLE 38. CHINA FLUNARIZINE HYDROCHLORIDE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 39. JAPAN FLUNARIZINE HYDROCHLORIDE, BY DRUG FORMULATION, 2022-2032 ($MILLION)
  • TABLE 40. JAPAN FLUNARIZINE HYDROCHLORIDE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 41. INDIA FLUNARIZINE HYDROCHLORIDE, BY DRUG FORMULATION, 2022-2032 ($MILLION)
  • TABLE 42. INDIA FLUNARIZINE HYDROCHLORIDE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 43. SOUTH KOREA FLUNARIZINE HYDROCHLORIDE, BY DRUG FORMULATION, 2022-2032 ($MILLION)
  • TABLE 44. SOUTH KOREA FLUNARIZINE HYDROCHLORIDE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 45. AUSTRALIA FLUNARIZINE HYDROCHLORIDE, BY DRUG FORMULATION, 2022-2032 ($MILLION)
  • TABLE 46. AUSTRALIA FLUNARIZINE HYDROCHLORIDE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 47. THAILAND FLUNARIZINE HYDROCHLORIDE, BY DRUG FORMULATION, 2022-2032 ($MILLION)
  • TABLE 48. THAILAND FLUNARIZINE HYDROCHLORIDE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 49. MALAYSIA FLUNARIZINE HYDROCHLORIDE, BY DRUG FORMULATION, 2022-2032 ($MILLION)
  • TABLE 50. MALAYSIA FLUNARIZINE HYDROCHLORIDE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 51. INDONESIA FLUNARIZINE HYDROCHLORIDE, BY DRUG FORMULATION, 2022-2032 ($MILLION)
  • TABLE 52. INDONESIA FLUNARIZINE HYDROCHLORIDE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 53. REST OF ASIA PACIFIC FLUNARIZINE HYDROCHLORIDE, BY DRUG FORMULATION, 2022-2032 ($MILLION)
  • TABLE 54. REST OF ASIA PACIFIC FLUNARIZINE HYDROCHLORIDE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 55. LAMEA FLUNARIZINE HYDROCHLORIDE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 56. LAMEA FLUNARIZINE HYDROCHLORIDE, BY DRUG FORMULATION, 2022-2032 ($MILLION)
  • TABLE 57. LAMEA FLUNARIZINE HYDROCHLORIDE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 58. BRAZIL FLUNARIZINE HYDROCHLORIDE, BY DRUG FORMULATION, 2022-2032 ($MILLION)
  • TABLE 59. BRAZIL FLUNARIZINE HYDROCHLORIDE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 60. SOUTH AFRICA FLUNARIZINE HYDROCHLORIDE, BY DRUG FORMULATION, 2022-2032 ($MILLION)
  • TABLE 61. SOUTH AFRICA FLUNARIZINE HYDROCHLORIDE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 62. SAUDI ARABIA FLUNARIZINE HYDROCHLORIDE, BY DRUG FORMULATION, 2022-2032 ($MILLION)
  • TABLE 63. SAUDI ARABIA FLUNARIZINE HYDROCHLORIDE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 64. UAE FLUNARIZINE HYDROCHLORIDE, BY DRUG FORMULATION, 2022-2032 ($MILLION)
  • TABLE 65. UAE FLUNARIZINE HYDROCHLORIDE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 66. ARGENTINA FLUNARIZINE HYDROCHLORIDE, BY DRUG FORMULATION, 2022-2032 ($MILLION)
  • TABLE 67. ARGENTINA FLUNARIZINE HYDROCHLORIDE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 68. REST OF LAMEA FLUNARIZINE HYDROCHLORIDE, BY DRUG FORMULATION, 2022-2032 ($MILLION)
  • TABLE 69. REST OF LAMEA FLUNARIZINE HYDROCHLORIDE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 70. JOHNSON AND JOHNSON: KEY EXECUTIVES
  • TABLE 71. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
  • TABLE 72. JOHNSON AND JOHNSON: OPERATING SEGMENTS
  • TABLE 73. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
  • TABLE 74. JOHNSON AND JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 75. CIPLA LIMITED: KEY EXECUTIVES
  • TABLE 76. CIPLA LIMITED: COMPANY SNAPSHOT
  • TABLE 77. CIPLA LIMITED: OPERATING SEGMENTS
  • TABLE 78. CIPLA LIMITED: PRODUCT PORTFOLIO
  • TABLE 79. CIPLA LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 80. TORRENT PHARMACEUTICALS LTD: KEY EXECUTIVES
  • TABLE 81. TORRENT PHARMACEUTICALS LTD: COMPANY SNAPSHOT
  • TABLE 82. TORRENT PHARMACEUTICALS LTD: OPERATING SEGMENTS
  • TABLE 83. TORRENT PHARMACEUTICALS LTD: PRODUCT PORTFOLIO
  • TABLE 84. TORRENT PHARMACEUTICALS LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 85. AA PHARMA INC: KEY EXECUTIVES
  • TABLE 86. AA PHARMA INC: COMPANY SNAPSHOT
  • TABLE 87. AA PHARMA INC: OPERATING SEGMENTS
  • TABLE 88. AA PHARMA INC: PRODUCT PORTFOLIO
  • TABLE 89. AA PHARMA INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 90. KARNATAKA ANTIBIOTICS AND PHARMACEUTICALS LTD: KEY EXECUTIVES
  • TABLE 91. KARNATAKA ANTIBIOTICS AND PHARMACEUTICALS LTD: COMPANY SNAPSHOT
  • TABLE 92. KARNATAKA ANTIBIOTICS AND PHARMACEUTICALS LTD: OPERATING SEGMENTS
  • TABLE 93. KARNATAKA ANTIBIOTICS AND PHARMACEUTICALS LTD: PRODUCT PORTFOLIO
  • TABLE 94. KARNATAKA ANTIBIOTICS AND PHARMACEUTICALS LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 95. CADILA PHARMACEUTICALS LTD: KEY EXECUTIVES
  • TABLE 96. CADILA PHARMACEUTICALS LTD: COMPANY SNAPSHOT
  • TABLE 97. CADILA PHARMACEUTICALS LTD: OPERATING SEGMENTS
  • TABLE 98. CADILA PHARMACEUTICALS LTD: PRODUCT PORTFOLIO
  • TABLE 99. CADILA PHARMACEUTICALS LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 100. ORCHID CHEMICALS AND PHARMACEUTICALS LTD: KEY EXECUTIVES
  • TABLE 101. ORCHID CHEMICALS AND PHARMACEUTICALS LTD: COMPANY SNAPSHOT
  • TABLE 102. ORCHID CHEMICALS AND PHARMACEUTICALS LTD: OPERATING SEGMENTS
  • TABLE 103. ORCHID CHEMICALS AND PHARMACEUTICALS LTD: PRODUCT PORTFOLIO
  • TABLE 104. ORCHID CHEMICALS AND PHARMACEUTICALS LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 105. FDC LTD: KEY EXECUTIVES
  • TABLE 106. FDC LTD: COMPANY SNAPSHOT
  • TABLE 107. FDC LTD: OPERATING SEGMENTS
  • TABLE 108. FDC LTD: PRODUCT PORTFOLIO
  • TABLE 109. FDC LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 110. ALKEM LABORATORIES LTD: KEY EXECUTIVES
  • TABLE 111. ALKEM LABORATORIES LTD: COMPANY SNAPSHOT
  • TABLE 112. ALKEM LABORATORIES LTD: OPERATING SEGMENTS
  • TABLE 113. ALKEM LABORATORIES LTD: PRODUCT PORTFOLIO
  • TABLE 114. ALKEM LABORATORIES LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 115. INTAS PHARMACEUTICALS LTD: KEY EXECUTIVES
  • TABLE 116. INTAS PHARMACEUTICALS LTD: COMPANY SNAPSHOT
  • TABLE 117. INTAS PHARMACEUTICALS LTD: OPERATING SEGMENTS
  • TABLE 118. INTAS PHARMACEUTICALS LTD: PRODUCT PORTFOLIO
  • TABLE 119. INTAS PHARMACEUTICALS LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL FLUNARIZINE HYDROCHLORIDE MARKET SEGMENTATION
  • FIGURE 2. GLOBAL FLUNARIZINE HYDROCHLORIDE MARKET
  • FIGURE 3. SEGMENTATION FLUNARIZINE HYDROCHLORIDE MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN FLUNARIZINE HYDROCHLORIDE MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALFLUNARIZINE HYDROCHLORIDE MARKET
  • FIGURE 11. FLUNARIZINE HYDROCHLORIDE MARKET SEGMENTATION, BY BY DRUG FORMULATION
  • FIGURE 12. FLUNARIZINE HYDROCHLORIDE MARKET FOR TABLETS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. FLUNARIZINE HYDROCHLORIDE MARKET FOR CAPSULES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. FLUNARIZINE HYDROCHLORIDE MARKET SEGMENTATION, BY BY APPLICATION
  • FIGURE 15. FLUNARIZINE HYDROCHLORIDE MARKET FOR MIGRAINE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. FLUNARIZINE HYDROCHLORIDE MARKET FOR VERTIGO, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 18. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 19. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 20. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 21. COMPETITIVE DASHBOARD
  • FIGURE 22. COMPETITIVE HEATMAP: FLUNARIZINE HYDROCHLORIDE MARKET
  • FIGURE 23. Top player positioning, 2022
  • FIGURE 24. JOHNSON AND JOHNSON: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 25. JOHNSON AND JOHNSON: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 26. JOHNSON AND JOHNSON: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 27. CIPLA LIMITED: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 28. CIPLA LIMITED: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 29. CIPLA LIMITED: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 30. TORRENT PHARMACEUTICALS LTD: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 31. TORRENT PHARMACEUTICALS LTD: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 32. TORRENT PHARMACEUTICALS LTD: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 33. AA PHARMA INC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 34. AA PHARMA INC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 35. AA PHARMA INC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 36. KARNATAKA ANTIBIOTICS AND PHARMACEUTICALS LTD: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 37. KARNATAKA ANTIBIOTICS AND PHARMACEUTICALS LTD: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 38. KARNATAKA ANTIBIOTICS AND PHARMACEUTICALS LTD: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 39. CADILA PHARMACEUTICALS LTD: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 40. CADILA PHARMACEUTICALS LTD: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 41. CADILA PHARMACEUTICALS LTD: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 42. ORCHID CHEMICALS AND PHARMACEUTICALS LTD: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 43. ORCHID CHEMICALS AND PHARMACEUTICALS LTD: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 44. ORCHID CHEMICALS AND PHARMACEUTICALS LTD: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 45. FDC LTD: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 46. FDC LTD: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 47. FDC LTD: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 48. ALKEM LABORATORIES LTD: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 49. ALKEM LABORATORIES LTD: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 50. ALKEM LABORATORIES LTD: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 51. INTAS PHARMACEUTICALS LTD: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 52. INTAS PHARMACEUTICALS LTD: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 53. INTAS PHARMACEUTICALS LTD: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Flunarizine Hydrochloride Market

Start reading.
This Report and over 67,071+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers